Project Sage Oldco (SIEN.Q) Stock Overview

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. More details

SIEN.Q fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 11% per year over the past 5 years

Risk Analysis

Negative shareholders equity

Highly volatile share price over the past 3 months

Does not have a meaningful market cap ($299K)

Shareholders have been diluted in the past year

+ 1 more risk

SIEN.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Project Sage Oldco, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Project Sage Oldco
Historical stock prices
Current Share Price	US$0.025
52 Week High	US$4.94
52 Week Low	US$0.019
Beta	1.97
1 Month Change	0%
3 Month Change	-86.26%
1 Year Change	-99.18%
3 Year Change	-99.97%
5 Year Change	-99.95%
Change since IPO	-99.99%

Recent updates

Analysis Article • Apr 17

Fewer Investors Than Expected Jumping On Sientra, Inc. (NASDAQ:SIEN)

Sientra, Inc.'s ( NASDAQ:SIEN ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right now...

Seeking Alpha • Oct 19

Sientra slides 18% on proposes stock offering

Sientra (NASDAQ:SIEN) intends to offer and sell in an underwritten public offering shares of common stock. Each share of common stock will be sold with a warrant to purchase one share of the company’s common stock. Underwriters are granted a 30-day option to purchase additional shares of common stock and/or additional common stock purchase warrants at the public offering price. All of the securities in the offering are to be offered by the Company. Currently, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Sientra intends to use any net proceeds received from this offering for general working capital purposes. Sientra stock fell 18.02% after-hours.

Seeking Alpha • Oct 12

Sientra refinances convertible debt at heavy premiums, sees Q3 revenue in-line

Sientra (NASDAQ:SIEN) rushed to reset its convertible notes financing at premiums as heavy as 272% of the stock's last close. The medical aesthetics firm Sientra told Wednesday it has entered into a $23M new senior secured convertible note refinancing with Deerfield Management at a conversion price of $1, representing a 35% premium on stock's last close. Also, the existing convertible note deal is amended to reduce the debt load by $10M to $50M at reset conversion price of $2.75, a whopping 272% premium on stock's close of $0.74. Maturity date for the existing notes is extended by 12 months to March 2026. "Proceeds from the financing are to be used to retire existing $21M senior secured term loan facility in full, and related financing expenses," the company said. On results front, Sientra reported its third quarter preliminary estimate at $21.5-$22.5M (+10-15%) compared to $21.65M consensus. The company is also reiterating prior full year 2022 revenue guidance of $90-95M vs. consensus of $90.85M. Net cash and cash equivalents anticipated to be $19M and free cash flow to range between $3 to $4M at the end of Q3 2022. "Our growth was driven by robust reconstruction demand and continued market share gains in augmentation. We look forward to continuing this momentum into 2023 and beyond as we prepare to launch our new fat transfer product and ground-breaking Allox2® PRO tissue expander," commented Sientra’s President and Chief Executive Officer Ron Menezes. Seeking Alpha's Quant Rating system assigns Strong Sell to SIEN, which sets the stock analysis stand apart from Wall Street's Strong Buy.

Seeking Alpha • Sep 20

Sientra gets regulatory nod to market breast implants in Saudi Arabia

Sientra (NASDAQ:SIEN) on Tuesday said it had got approval from Saudi Arabia's drug regulator to market its line of silicone gel breast implants in the Middle Eastern country. The Saudi Food & Drug Authority approved the marketing of SIEN's smooth surface, High-Strength Cohesive (HSC and HSC+) silicone gel breast implants, the company said in a statement. "As the largest country in the Middle East and (the Gulf Cooperation Council), and a growing aesthetics hub for the region, we see the Kingdom of Saudi Arabia as the tremendous launchpad for our international expansion efforts into the Middle East region," said SIEN CEO Ron Menezes. The company will market its breast implants in the GCC through its local partner Rose Aljazera. SIEN stock -4% to $0.56 in premarket trading.

Seeking Alpha • Aug 11

Sientra GAAP EPS of -$0.29 misses by $0.06, revenue of $21.5M misses by $2.26M

Sientra press release (NASDAQ:SIEN): Q2 GAAP EPS of -$0.29 misses by $0.06. Revenue of $21.5M (+7.0% Y/Y) misses by $2.26M. Ron Menezes, Sientra’s President and Chief Executive Officer, said, “With our advanced technology, industry-leading safety profile, and innovative programs, we have been able to significantly outperform the market in both reconstruction and augmentation. We are encouraged by the high level of re-order rates we are seeing as well as overall new account growth, which we believe sets us up for continued growth in 2022 and beyond." The company is adjusting full year's revenue guidance to a range of $90M to $95M, down from prior guidance of $93M to $97M and consensus of $95.25M. The new guidance reflects growth of 11% to 18% compared to sales of $80.7M in 2021.

Seeking Alpha • Jul 06

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Sientra (NASDAQ:SIEN) on Wednesday said the U.S. FDA had approved its breast implant product for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. SIEN said the product, Low Plus Profile Projection Breast Implant, would be commercially available for certified and eligible plastic surgeons in the U.S. in late July. SIEN said it would be first implant maker in the U.S. to offer 80cc and 110cc gel implants, with the two new sizes bringing more options to surgeons and their patients. SIEN stock slightly lower in volatile early trading.

Analysis Article • Apr 16

Sientra (NASDAQ:SIEN) Is Carrying A Fair Bit Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analysis Article • Jan 06

Is Sientra (NASDAQ:SIEN) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

	SIEN.Q	US Medical Equipment	US Market
7D	-37.3%	-3.5%	1.5%
1Y	-99.2%	-22.1%	28.6%

Return vs Industry: SIEN.Q underperformed the US Medical Equipment industry which returned -1.4% over the past year.

Return vs Market: SIEN.Q underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is SIEN.Q's price volatile compared to industry and market?
SIEN.Q volatility
SIEN.Q Average Weekly Movement	97.8%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: SIEN.Q's share price has been volatile over the past 3 months.

Volatility Over Time: SIEN.Q's weekly volatility has increased from 56% to 98% over the past year.

About the Company

Founded	Employees	CEO	Website
2003	304	Ron Menezes	sientra.com

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides fat transfer systems; body contouring products; facial and nasal implants; saline filled sizers.

Project Sage Oldco, Inc. Fundamentals Summary

How do Project Sage Oldco's earnings and revenue compare to its market cap?
SIEN.Q fundamental statistics
Market cap	US$298.94k
Earnings (TTM)	-US$59.33m
Revenue (TTM)	US$90.30m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is SIEN.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SIEN.Q income statement (TTM)
Revenue	US$90.30m
Cost of Revenue	US$52.28m
Gross Profit	US$38.02m
Other Expenses	US$97.35m
Earnings	-US$59.33m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.96
Gross Margin	42.11%
Net Profit Margin	-65.71%
Debt/Equity Ratio	-183.5%

How did SIEN.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/07/01 21:34
End of Day Share Price	2024/07/01 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Project Sage Oldco, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kyle Rose	Canaccord Genuity
Kyle Bauser	Colliers Securities
Alexander Nowak	Craig-Hallum Capital Group LLC

Project Sage Oldco (SIEN.Q) Stock Overview

Rewards

Risk Analysis

Project Sage Oldco, Inc. Competitors

Surgalign Holdings

Procyon

InVitro International

Vycor Medical

Price History & Performance

Recent News & Updates

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Sientra, Inc. announced delayed annual 10-K filing

Recent updates

Second Amended Liquidation Plan Approved for Sientra, Inc.

Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

First Motion for Exclusivity Period Extension Filed by Sientra, Inc.

Joint Reorganization Plan and Disclosure Statement Filed by Sientra, Inc.

The Nasdaq Stock Market to Delist the Common Stock of Sientra

Sientra, Inc. announced delayed annual 10-K filing

Sientra, Inc.(OTCPK:SIEN.Q) dropped from NASDAQ Composite Index

Motion for Joint Administration Approved for Sientra, Inc.

Motion for Asset Sale Filed by Sientra, Inc.

Sientra, Inc. Filed for Bankruptcy

Motion for Joint Administration Filed by Sientra, Inc.

Sientra Receives Non-Compliance Notice from Nasdaq

Consensus EPS estimates fall by 15%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

Sientra, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Sientra, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Sientra, Inc. Appoints Alexander W. Casdin to the Company’s Board of Directors, Effective June 15, 2023

Sientra Announces FDA-Clearance of Next Generation Allox2 Pro Tissue Expander

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sientra, Inc. Provides Earnings Guidance for the Full Year of 2023

Fewer Investors Than Expected Jumping On Sientra, Inc. (NASDAQ:SIEN)

Full year 2022 earnings: EPS misses analyst expectations

Insider recently bought US$933k worth of stock

Price target decreased to US$2.08

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sientra slides 18% on proposes stock offering

Sientra refinances convertible debt at heavy premiums, sees Q3 revenue in-line

Sientra gets regulatory nod to market breast implants in Saudi Arabia

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Sientra GAAP EPS of -$0.29 misses by $0.06, revenue of $21.5M misses by $2.26M

FDA approves Sientra’s breast implant product for breast augmentation, reconstruction

Price target decreased to US$6.33

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.83

Price target decreased to US$7.67